Drugs / Flumatinib
Trials 9 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06530810 Background | Jul 2024 → May 2026 overdue | leukemia, myeloid, accelerated-phase | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04933526 Comparator | Jul 2021 → Apr 2023 | chronic myeloid leukemia | Shenzhen Second People's Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flumatinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04933526 ↗ |
| Action | Inhibit | “Flumatinib has been shown to be a more potent inhibitor of BCR-ABL1 tyrosine kinase than imatinib.” PMID 32928796 ↗ Sep 2020 |
| Modality | Small molecule | “Flumatinib is the first approved second generation TKI in China and a derivative of imatinib.” NCT04375683 ↗ |
| Route | Oral | “The starting daily oral dose of Flumatinib is 600mg” NCT02511340 ↗ |
| Target | ABL1 | “Flumatinib, a TKI with more potent binding affinity for BCR-ABL1 tyrosine kinase than imatinib” NCT05071482 ↗ |